Sumgen Biotech's Antibody Drug CMC R&D Center in Hangzhou Binjiang Tianhe High-Tech Park is officially established. This is the second R&D center established by Sumgen Biotech since the opening of its Beijing New Drug R&D Center in 2017.
Hangzhou Sumgen Biotech Co., Ltd. (hereinafter "Sumgen Biotech") recently announced that its Antibody Drug CMC R&D Center in Hangzhou Binjiang Tianhe High-Tech Park is officially established. This is the second R&D center established by Sumgen Biotech since the opening of its Beijing New Drug R&D Center in 2017.
The Hangzhou CMC R&D Center is established by Dr. Miao, who has over 10 years of experience in antibody drug development, registration and commercialization. With a total area of about 1,000 m2, the center is built with equipment required for cell strain construction (including upstream process development, medium development, downstream sorting, and monoclonal antibody imaging), upstream process development (Kuhner shakers, Applikon 3L mini tank, and Nova biochemical analyzer), and quality analysis (AKTA Avant purification system, Agilent HPLC, capillary electrophoresis, and MD microplate reader).
The establishment of the Hangzhou CMC R&D Center allows seamless integration with the Beijing New Drug R&D Center, which not only provides Sumgen Biotech with a complete R&D system for antibody discovery, cell strain construction, process development, and quality studies, but also accelerates the clinical application of subsequent products.
Dr. Lv, founder and chairman of Sumgen Biotech, stated that "Establishing the Hangzhou CMC R&D Center has further improved Sumgen Biotech's pharmaceutical research platform and is an important milestone in the company's development. The opening of the Hangzhou Center not only signifies a new phase for Sumgen Biotech's innovative antibody development, but it also lays a solid foundation for the subsequent construction of an antibody drug production base for the Company."
Supported by a highly experienced R&D team and state-of-art R&D equipment, the Hangzhou CMC R&D Center is always seeking for talents to join the team. The Company will provide suitable candidates with competitive salaries and promising career development prospects. Sumgen Biotech sincerely invites you to join us!
About Sumgen Biotech
Sumgen Biotech specializes in the R&D and commercialization of antibody therapeutics for cancer and other serious diseases. Since its founding, we are led by a professional team and consultative committee made up of members of Chinese Academy of Science and Engineering and other experts highly experienced in the development of antibody drugs and their industrialization. A Beijing R&D center has been established for new antibody screening and a Hangzhou R&D center has been established for CMC research. We successfully developed an optimized new drug R&D platform and a pharmaceutical research platform. Our proprietary product pipeline currently is focused on broad immuno-oncology targets, with tumor immunotherapy, ADC drugs, and bispecific antibodies in the clinical study stage. We plan to build a large-scale antibody drug production base in accordance with the GMP standards of CFDA, US FDA and EU EMA in the future.
Contact:
Shiwei Miao, miaoshiwei@sumgenbio.com
Wenhua Dong, dongwenhua@sumgenbio.com
Copyright Rm. 301, F3, Building C, Block 2, No. 688, Bin'an Road, Changhe Zhejiang ICP Filing No. 18039044
